Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 380 participants.
Also called NCT02517866
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 380 participants
- Sponsor
- Registry
-
NCT02517866 -
U1111-1156-8501
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Taiwan, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT02517866. Allocation not applicable; no masking; primary purpose treatment. Start 2015-07-13 (actual); primary completion 2016-11-15 (actual). Results posted on 2019-03-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
- Condition
- Essential Hypertension
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Azilsartan Medoxomil
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct02517866- Content hash
319a5d0c4cf4f9297fd3ea4e38d7dce3867135211b9aaee0969f61b2d41b649a